

November 11, 2025

|   |   |
|---|---|
| <b>Listing Department,<br/>National Stock Exchange of India Limited<br/>Exchange Plaza, Bandra-Kurla Complex,<br/>Bandra (E),<br/>Mumbai – 400 051</b><br><br><b>NSE Symbol: ARTEMISMED</b> | <b>Listing Department,<br/>BSE Limited<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai – 400 001</b><br><br><b>Scrip Code: 542919</b> |
|---|---|

**Sub: Earning Presentation – Q2 and H1 FY 26**

Dear Sir/Ma'am,

With reference to the captioned subject, please find attached herewith the earning presentation for the quarter/half year ended September 30, 2025.

The presentation is also available on the website of the Company at [www.artemishospitals.com/investors](http://www.artemishospitals.com/investors).

This is for your information and records.

Thanking you,

Yours faithfully,

**For Artemis Medicare Services Limited**

**Poonam Makkar**

**Company Secretary & Compliance Officer**

**Encl:** As above





**Investors**  
Earning Presentation  
Q2 and H1 FY 26

Established  
in **2007**

Spread across a total  
area of 8.23 acres.

Artemis Hospitals,  
Ranks Among The Best  
Multi Speciality Hospitals  
in Delhi-NCR, India.

# Performance Highlights

## Q2 FY 26

YoY

### Revenue from Operations

Q2 FY 26  
INR 26,059 Lacs

▲ 16.4%

Q2 FY 25  
INR 22,392 Lacs

### Revenue from Operations

Q2 FY 26  
INR 27,470 Lacs

▲ 13.8%

Q2 FY 25  
INR 24,142 Lacs

### EBITDA

Q2 FY 26  
INR 5,827 Lacs

▲ 17.2%

Q2 FY 25  
INR 4,970 Lacs

### EBITDA Margin

Q2 FY 26  
21.2%

▲ 63 bps

Q2 FY 25  
20.6%

### PBT

Q2 FY 26  
INR 3,938 Lacs

▲ 28.9%

Q2 FY 25  
INR 3,055 Lacs

### PAT

Q2 FY 26  
INR 3,000 Lacs

▲ 35.6%

Q2 FY 25  
INR 2,213 Lacs

QoQ

### Revenue from Operations

Q2 FY 26  
INR 26,059 Lacs

▲ 8.0%

Q1 FY 26  
INR 24,125 Lacs

### Revenue from Operations

Q2 FY 26  
INR 27,470 Lacs

▲ 7.7%

Q1 FY 26  
INR 25,496 Lacs

### EBITDA

Q2 FY 26  
INR 5,827 Lacs

▲ 20.6%

Q1 FY 26  
INR 4,832 Lacs

### EBITDA Margin

Q2 FY 26  
21.2%

▲ 226 bps

Q1 FY 26  
19.0%

### PBT

Q2 FY 26  
INR 3,938 Lacs

▲ 32.2%

Q1 FY 26  
INR 2,978 Lacs

### PAT

Q2 FY 26  
INR 3,000 Lacs

▲ 41.5%

Q1 FY 26  
INR 2,120 Lacs



Gurgaon



Consolidated

# Welcome to the World of Artemis

Artemis Hospitals is a healthcare venture launched by the promoters of the Apollo Tyres Group. Our portfolio includes a **700** bed super speciality hospital in Gurugram (Delhi-NCR), India and further expanding to **~2,000 beds** by 2028.

## Top of the line Advanced Technology

**14** Centres of Excellence

**40+** Medical Specialities

**500+** Doctors

## State-of-the-Art Tertiary Care Hospital

**1st** JCI Accredited Hospital in Gurgaon

**100+** Business Tie-ups with Corporates

**100+** Countries Patients



# Our Vision, Mission & Core Values



## OUR VISION

To create an Integrated World Class Healthcare System, Fostering, Protecting, Sustaining and Restoring Health through Best in Class Medical Practices and Cutting Edge Technology developed through in depth Research carried out by the World's Best Scientific Minds.



## MISSION

Deliver world class patient care services

Excel in the delivery of specialized medical care supported by comprehensive research and education

Be the preferred choice for the world's leading medical professionals and scientific minds

Develop, apply, evaluate and share new technology

Be an active partner in local community initiatives and contribute to its well-being and development



## CORE VALUES

The corporate value system at Artemis Hospitals is founded on three pillars

### Service, Compassion & Integrity

Care for Customer

Respect for Associates

Excellence through Teamwork

Always Learning

Trust Mutually

Ethical Practices



Emergency &  
Trauma Centre



Heart Centre



Cancer Centre



Dermatology, Cosmetology  
& Plastic Surgery Centre



Neurosciences  
Centre



Joint Replacement &  
Orthopaedics Centre



Minimally Invasive &  
Bariatric Surgery Centre



Gastrosiences  
Centre



Organ Transplant  
Centre



Woman & Child  
Centre



Pulmonology & Critical  
Centre



Pain Medicine &  
Palliative Care Centre




Heart & Lung  
Transplant




Geriatric  
Medicine

The Super Speciality Care at  
**Artemis Hospitals**

# Centres of Excellence





Artemis Hospital provides  
comprehensive treatments for a  
wide variety of medical specialities

# Our Services

- **Anaesthesia**
- **Blood Center & Blood Transfusion Services**
- **Cardiology & CTVS** (Interventional & Non-Interventional Cardiology, Paediatric Cardiac Surgery, Paediatric Cardiology & Cardiac Rehab)
- **Critical Care & ICU** (General ICU, Neonatal ICU, Pediatric ICU, Neuro ICU, CTVS ICU)
- **Dentistry**
- **Dermatology & Cosmetology**
- **Dietetics**
- **Emergency & Trauma Services** (Ambulance Services)
- **Endocrinology** (Adult & Paediatrics)
- **ENT** (Audiometry, Speech and Swallow Therapy)
- **General Surgery** (Minimally Invasive Surgery, Bariatric Surgery & Robotic Surgery)
- **Gastroenterology & Hepatology** (Adult & Paediatrics) Advance Interventional GI Endoscopy | Third Space & Weight Management | Biliary & Pancreatology | Luminal Gastroenterology
- **Geriatric Medicine & Longevity Clinic**
- **Heart & Lung Transplant Centre**
- **Internal Medicine & Preventive Health Check**
- **Mental Health & Behavioural Sciences**
- **Nephrology** (Dialysis & Renal Transplant)
- **Neurology, Neurosurgery, Neuro Spine & Neurointerventional Surgery**
- **Obstetrics & Gynaecology**
- **Ophthalmology** (Including Cornea Transplant)
- **Orthopaedics** (Joint Replacement, Ortho Spine, Paediatrics Orthopaedics, Sports & Trauma, Robotics Surgery)
- **Organ Transplant** (Bone Marrow Transplant, Cornea Transplant, Kidney Transplant & Liver Transplant)
- **Oncology** (Medical, Surgical, Radiation, Nuclear Medicine & Robotics)
- **Paediatric & Allied Services** (General, Cardiac, Surgery, Neurology, Endocrinology, Gastro, Ortho)
- **Pain Management & Palliative Care**
- **Physiotherapy, Occupational Therapy & Rehabilitation**
- **Fetal Medicine & Medical Genetics**
- **Plastic, Reconstructive & Cosmetic Surgery**
- **Pulmonology & Respiratory Medicine** (including Sleep Medicine)
- **Urology, Uro-Oncology & Robotics**
- **Pharmacy Services**
- **IVF and Reproductive Medicine** (ART)
- **Lab Services** (With Lab Sample Collection)
- **Radiology**
- **Rheumatology** (Adult & Paediatrics)
- **Special Child Centre**

# Chairman's Message

## Onkar Kanwar

Chairman

Artemis Hospitals & Apollo Tyres Ltd.

Life is our greatest gift, where every moment is as new as it is special. Life is about living every second to the fullest. About making every day an experience to enjoy and cherish. The vital ingredient needed to make this a reality is good health. Fitness of mind and body ensures that nothing gets in the way of our freedom of spirit.

Our being alive is not merely about adding years to our life, but adding life to our years. At Artemis, we have created a sanctuary of good health. With state-of-the-art technology, systems, processes and infrastructure designed to a degree of detail, that ensures comfort and satisfaction, at all times.

Driving this facility to your benefit is a team of caring and accomplished professionals, educated at the best medical schools and skill-tested at the most respected hospitals worldwide.

Wishing you good health and happiness!

The Visionary Behind



# Managing Director's Message

## Dr. Devlina Chakravarty

Managing Director, Artemis Hospitals

At Artemis Hospitals, our vision has always been to redefine healthcare by combining clinical excellence with genuine compassion. We believe that true progress in medicine comes not only from advanced technology and innovation, but from an unrelenting commitment to the people we serve.

Our mission is to create a healthcare ecosystem where patients feel seen, heard, and cared for — where every touchpoint reflects trust, empathy, and integrity.

As we grow, our focus remains clear: to make quality healthcare accessible while maintaining the highest standards of ethics and patient safety. This journey is not just about building hospitals; it's about shaping a future where healthcare becomes more humane, inclusive, and transformative.

At Artemis, we're not just treating illnesses — we're empowering lives, with ethical and transparent practices.

The Patron



# The Board of Directors

Strong governance at Artemis Hospital is rooted in the leadership of its Board of Directors.



**Mr. Onkar Kanwar**  
Chairman & Non-Executive  
Director



**Dr. Devlina Chakravarty**  
Managing Director



**Ms. Shalini Kanwar Chand**  
Non-Executive Director



**Mr. Neeraj Singh Kanwar**  
Non-Executive Director



**Mr. Sunam Sarkar**  
Non-Executive Director



**Mr. Vinod Rai**  
Independent Director



**Ms. Pallavi Shardul Shroff**  
Independent Director



**Mr. Akshaykumar Narendrasinhji  
Chudasama**  
Independent Director



**Mr. Sanjib Sen**  
Independent Director



**Mr. Sunil Tandon**  
Independent Director

# The Core Management Team

The team takes the lead in driving day-to-day operations, ensuring seamless coordination across departments and delivering high-quality patient care.



**Mr. Sanjiv Kumar Kothari**  
Chief Financial Officer



**Flt. Lt. Saras Malik**  
Chief People Officer



**Dr. Manju Aggarwal**  
Chief Medical Services &  
Chairperson - Nephrology



**Dr. Anjali Kaul**  
Deputy Chief Medical Services &  
Medical Superintendent



**Dr. Vishal Arora**  
Chief Business Officer



**Mr. Pradeep Kumar Saha**  
Group Chief Information Officer



**Mr. Rudra Narayan Acharjee**  
Head-Investor Relations, M&A and  
Organization Growth Strategy



**Mr. Vivek Singh**  
Head-Legal



**Ms. Poonam Makkar**  
Company Secretary &  
Compliance Officer

# Our Advanced Technologies



North India's First  
**CyberKnife® M6™**



**da Vinci®**  
Robotic Surgical  
System



**CUVIS JOINT**  
Robotic System  
For Joint Replacement



**O-ARM II**  
Surgical Imaging  
System



**Epic CVXI**  
ECHO Machine



**Symbia Intevo with xSPECT**  
SPECT/CT™  
(Gamma Camera)



**3D Biplane Laboratory**  
High Definition & CT like  
3D Imaging



**1.5 T Scanner**  
For Imaging  
Excellence



**Siemens Ysio Max**  
High End Digital Radiography  
System with Robotic Arms



**3T MRI system**  
MAGNETOM Lumina



**EchoNavigator**  
State-of-the-Art  
Cath Lab




**VABB**  
Breast Biopsy  
System



**4D Affinity 50**  
Ultrasound  
Machine



**Biograph  
mCT™**  
PET/CT



**CT Philips Incisive**  
128 slice with motion free  
Cardiac Precise Imaging

# Our Accreditations

Established National & International Accreditation Standards in achieving our goals of providing quality clinical care and patient services.



Artemis is the first Hospital in Gurugram to receive accreditation by Joint Commission International (JCI), USA



National Accreditation Board for Hospitals & Healthcare Providers



National Accreditation Board for Hospitals & Healthcare Providers  
Certified Nursing Services



National Accreditation Board for Hospitals & Healthcare Providers  
Certified Emergency Services  
(Certificate Awaited)



National Accreditation Board for Hospitals & Healthcare Providers Accredited  
Blood Bank / Blood Centre



National Accreditation Board for Hospitals & Healthcare Providers -  
Ethics Committee



The Laboratory Services are Accredited  
by NABL based on ISO 15189:2012 for  
a specified scope of tests



Intertek ISO 27001  
Certificate

# Strategic Growth Vision



## Artemis Hospital, Gurgaon

Opened the third tower, taking the capacity to **700 beds**, making it one of the largest hospitals, in Delhi-NCR.

Received a **Platinum Green Building Certification**, entitles a **15% increase in FAR**, thereby enables to add **100+ beds** to support its long term growth.

Further, Purchase of additional FAR to 2.15, which would add another ~ **200 beds** taking the capacity to **1,000 beds**.



## Expansion in Super Speciality Segment

Announced **300+ bed super speciality hospital in Raipur**.

A binding MOU with conditions precedent for **650+ bed super speciality hospital in South Delhi**

Further capacity enhancement by adding super speciality hospitals in the group in Delhi NCR / select Tier – 2 cities




## Overseas Operations and Management

Operating our first hospital with **80 beds** branded as 'Artemis Curepipe Hospital', which started in FY 24

Planning to add **2 more hospitals** with total facility of **200 beds**

Further plans in place to increase Artemis footprint in other international locations

# Shareholding Pattern



Note : As on 30<sup>th</sup> September, 2025

| Share Holders  | No of Share | Share Holding % | Category        |
|--|-------------|-----------------|-----------------|
| Constructive Finance Pvt Ltd                         | 92,425,790  | 66.5%           | Promoters       |
| Governor of Kerala                                   | 6,749,600   | 4.9%            | Government      |
| Devlina Chakravarty                                  | 4,567,980   | 3.3%            | Directors       |
| Kerala State Industrial Development Corporation      | 3,000,000   | 2.2%            | Government      |
| HSBC Focused Fund                                    | 1,250,000   | 0.9%            | DIIs            |
| Bank of India  | 1,198,100   | 0.9%            | DIIs            |
| PGIM India Equity Growth Opportunities Fund-Series I | 1,068,035   | 0.8%            | DIIs            |
| LIC Mutual Fund                                      | 972,569     | 0.7%            | DIIs            |
| Alok Agarwal   | 761,660     | 0.5%            | Retail & Others |
| SNK Investments Private Limited                      | 675,430     | 0.5%            | Retail & Others |
| ICICI Prudential Life Insurance Company Limited      | 575,750     | 0.4%            | DIIs            |
| Golconda Estates Pvt Ltd                             | 574,220     | 0.4%            | Retail & Other  |
| Bandhan Mutual Fund                                  | 566,897     | 0.4%            | DIIs            |

# Financial Highlights

## Q2 FY26 Consolidated

- Revenue from Operations of INR 275 Cr, growth of 13.8% on YoY and 7.7% on QoQ basis
- EBITDA of INR 58 Cr, growth of 17.2% on YoY and 20.6% on QoQ basis.
- EBITDA margin of 21.2% vs. 20.6% in Q2 FY25 and 19.0% in Q1 FY26.
- PAT of INR 30 Cr in Q2 FY 26, growth of 35.6% on YoY and 41.5% on QoQ basis.
- Consolidated Diluted EPS for Q2 FY26 of INR 1.89, growth of 34.0% on YoY basis.

## H1 FY26 Consolidated

- Revenue from Operations of INR 530 Cr, growth of 14.0% on YoY basis
- EBITDA of INR 107 Cr, growth of 18.1% on YoY basis.
- EBITDA margin of 20.1% vs. 19.4% in H1 FY25.
- PAT of INR 51 Cr in H1 FY26 against INR 39 Cr in H1 FY 25, growth of 32.5%
- Consolidated Diluted EPS for H1 FY26 of INR 3.24, growth of 27.6% on YoY basis.

| Particulars (INR in Lacs)                                | Consolidated - FY26 |          |          |       |       |          |          |       |
|--|---------------------|----------|----------|-------|-------|----------|----------|-------|
|  | Q2 FY 26            | Q1 FY 26 | Q2 FY 25 | QoQ   | YoY   | H1 FY 26 | H1 FY 25 | YoY   |
| Total Income   | 28,236              | 26,189   | 24,886   | 7.8%  | 13.5% | 54,425   | 47,647   | 14.2% |
| Less: Other Income                                       | 765                 | 693      | 744      | 10.5% | 2.9%  | 1,458    | 1,184    | 23.1% |
| Revenue from Operations                                  | 27,470              | 25,496   | 24,142   | 7.7%  | 13.8% | 52,966   | 46,463   | 14.0% |
| PBT  | 3,938               | 2,978    | 3,055    | 32.2% | 28.9% | 6,916    | 5,219    | 32.5% |
| Finance Cost   | 719                 | 738      | 798      | -2.7% | -9.9% | 1,457    | 1,611    | -9.6% |
| EBIT   | 4,656               | 3,717    | 3,853    | 25.3% | 20.8% | 8,373    | 6,830    | 22.6% |
| Depreciation and amortisation expenses                   | 1,171               | 1,116    | 1,117    | 5.0%  | 4.8%  | 2,287    | 2,197    | 4.1%  |
| EBITDA (Incl. Other Income)                              | 5,827               | 4,832    | 4,970    | 20.6% | 17.2% | 10,660   | 9,028    | 18.1% |
| EBITDA (Incl. Other Income) % to Revenue from Operations | 21.2%               | 19.0%    | 20.6%    |       |       | 20.1%    | 19.4%    |       |
| Less: Other Income                                       | 765                 | 693      | 744      | 10.5% | 2.9%  | 1,458    | 1,184    | 23.1% |
| EBITDA (Excl. Other Income)                              | 5,062               | 4,139    | 4,226    | 22.3% | 19.8% | 9,201    | 7,843    | 17.3% |
| EBITDA (Excl. Other Income) % to Revenue from Operations | 18.4%               | 16.2%    | 17.5%    |       |       | 17.4%    | 16.9%    |       |

# Operational Highlights

## Q2 FY26 Gurgaon

- IP Volumes of 8,740, grew by 9.0% on YoY and 6.0% on QoQ basis.
- ARPOB of INR 81,248, growth of 7.4% on YoY basis.




## H1 FY26 Gurgaon

- IP Volumes of 16,982, grew by 8.0% on YoY basis
- ARPOB of INR 80,907, growth of 7.5% on YoY basis.

| Particulars                           | Q2 FY 26 | Q1 FY 26 | Q2 FY 25 | H1 FY 26 | H1 FY 25 |
|---------------------------------------|----------|----------|----------|----------|----------|
| Total Bed Capacity                    | 700      | 700      | 700      | 700      | 700      |
| Census Beds                           | 600      | 600      | 600      | 600      | 600      |
| Non Census Beds                       | 100      | 100      | 100      | 100      | 100      |
| Operational Beds                      | 544      | 543      | 466      | 543      | 461      |
| Occupied Beds                         | 349      | 332      | 323      | 341      | 314      |
| Occupancy (%)                         | 64.1%    | 61.2%    | 69.4%    | 62.7%    | 68.0%    |
| IP Volume                             | 8,740    | 8,242    | 8,015    | 16,982   | 15,726   |
| ARPOB (INR)                           | 81,248   | 79,752   | 75,647   | 80,907   | 75,248   |
| ALOS (Days)                           | 3.7      | 3.7      | 3.7      | 3.7      | 3.7      |
| Total Income (INR in Lacs)            | 26,835   | 24,818   | 23,138   | 51,653   | 44,360   |
| Revenue from Operations (INR in Lacs) | 26,059   | 24,125   | 22,392   | 50,184   | 43,191   |
| EBITDA (INR in Lacs)                  | 5,828    | 4,953    | 4,985    | 10,781   | 9,133    |
| EBITDA % to Revenue from Operations   | 22.4%    | 20.5%    | 22.3%    | 21.5%    | 21.1%    |
| EBIT (INR in Lacs)                    | 4,824    | 4,007    | 4,123    | 8,831    | 7,449    |
| PBT (INR in Lacs)                     | 4,190    | 3,356    | 3,468    | 7,546    | 6,139    |
| PAT (INR in Lacs)                     | 3,210    | 2,491    | 2,616    | 5,701    | 4,765    |

# Q2 & H1 FY 26

## Revenue by Speciality - Gurgaon




Oncology  
Cardiology  
Nephrology  
Liver Transplant

Neuro  
Internal Medicine  
Gastroenterology  
Obs & Gynae

Orthopaedics  
General Surgery  
Pulmonology  
Other Specialities

# Q2 & H1 FY 26

## Revenue by Payor - Gurgaon



# Recent Milestones

## Artemis In News



### Artemis Hospitals bring advanced Heart & Lung Transplant Centre to North India

Artemis Hospitals, a leading healthcare provider in North India, has announced the launch of its advanced Heart & Lung Transplant Centre. The centre, located in Gurgaon, is the first of its kind in the region and is equipped with state-of-the-art facilities and a team of highly skilled medical professionals. The centre will provide comprehensive care for patients requiring heart and lung transplants, including pre-operative evaluation, surgery, and post-operative care. The launch of this centre is a significant milestone for Artemis Hospitals, demonstrating its commitment to providing advanced medical services to its patients.



A celebration of the launch of the new Heart & Lung Transplant Centre at Artemis Hospitals.

### Rare arterial switch surgery saves baby at city pvt hospital

By Isha Patel | [www.ishapatel.com](#)

Gurgaon: A rare and high-risk cardiac surgery was successfully performed on a newborn suffering from transposition of great arteries (TGA), a life-threatening congenital heart defect. The baby, born weighing just 3.5kg, underwent the complex arterial switch operation recently two weeks after birth. Doctors at Artemis Hospital completed the surgery. TGA is a critical condition in which the two main arteries connecting the heart are reversed, severely disrupting the flow of oxygen to the body. Without timely surgical intervention, the condition can be fatal.

What made the case even more challenging was the newborn's fragile condition and extremely low birth weight, which posed surgical and post-operative risks. The baby was one of a set of twins born to a family in Gurgaon. While his twin sibling was born healthy, the younger brother's congenital defect was identified shortly after birth, prompting immediate medical intervention. The surgery was carried out when the baby was just two weeks old. This procedure is the definitive treatment for TGA and involves repositioning the major arteries to restore normal blood circulation. Without timely intervention, this condition is almost invariably fatal, doctors said.

The surgery was led by Dr. Anand R. Sharma, a senior cardiologist and heart surgeon, and Dr. Anand R. Sharma, a senior cardiologist and heart surgeon. The surgery was performed at Artemis Hospital, a multi-specialty hospital in Gurgaon. The hospital has a dedicated cardiac surgery unit, staffed by a team of highly skilled medical professionals.

"This was one of the most complex neonatal cases we handled," said Dr. Sharma. "The baby's condition was extremely critical due to the nature of the defect and his low birth weight. However, with early diagnosis, precise surgical planning, and comprehensive post-operative care, we were able to ensure a successful outcome." After the surgery, the newborn was closely monitored in the neonatal intensive care unit, where he steadily showed signs of recovery. Doctors report that he is now stable and recovering well.

### Nine-year-old had daily blackouts for 5 months: How AI tool helped doctors diagnose a rare condition in record time

By Isha Patel | [www.ishapatel.com](#)



Diagnosing a neurological problem, the family consulted neurologists everywhere who did a battery of tests. [File]  
For five months, nine-year-old Isha (name changed) would faint every day. Every single day, without so much as a warning, the boy would pass his aunts, complain of a strange sensation, pain and then collapse. His father, a newspaper in Gurgaon, stopped work on most days to monitor his son's sudden attacks. "Every time he touched his ears, my heart would stop. I knew what was coming next," he says. Doctor after doctor would attempt a diagnosis but the fainting spells would not stop. Till they used AI to zero in on a rare neurological condition that troubled the boy.

### Breaking barriers: 4 lives saved by rare liver transplants at Gurgaon hospital

Isha Patel | [THN](#) / Oct 24, 2025, 06:18 IST

[Share](#) [Print](#) [AA](#) [Read More](#)

Artemis Hospital in Gurgaon achieved a rare feat by successfully completing four ABO-incompatible liver transplants within a single month. Two Indian patients and two from Central Asia received new livers despite blood group mismatches. Doctors at [Read More](#)

### THE WEEK

#### Haryana's First Evolut FX+ TAVR

#### A New Era in Heart Valve Therapy at Artemis Hospitals



# Extending our Legacy into Central India!



## Artemis Hospitals Soon Opening **300+ beds Super-speciality Hospital** in Raipur, Chhattisgarh.

Backed by Advanced State-of-the-Art  
Infrastructure

---

**Total Built up area**  
2,70,000 sqft

---

**Building Configuration**  
2 basement + Ground + 6 floors

---

**Top Specialities**  
Oncology, Cardiology, Neurology, Orthopaedics,  
Gastro and Others

---

**Expected Operational Date**  
March 2026

# Q2 & H1 FY 26 Financial Performance (Consolidated)

| Particulars (INR in Lacs)              | Q2 FY 26     | Q2 FY 25     | YoY%         | Q1 FY 26     | QoQ%         | H1 FY 26      | H1 FY 25     | YoY%         |
|--|--------------|--------------|--------------|--------------|--------------|---------------|--------------|--------------|
| Revenue from Operations                | 27,470       | 24,142       | 13.8%        | 25,496       | 7.7%         | 52,966        | 46,463       | 14.0%        |
| Other Income                           | 765          | 744          | 2.9%         | 693          | 10.5%        | 1,458         | 1,184        | 23.1%        |
| Total Income                           | 28,236       | 24,886       | 13.5%        | 26,189       | 7.8%         | 54,425        | 47,647       | 14.2%        |
| Operative Expenses                     | 16,547       | 14,490       | 14.2%        | 15,727       | 5.2%         | 32,273        | 27,886       | 15.7%        |
| Employee Benefit Expenses              | 3,927        | 3,587        | 9.5%         | 3,840        | 2.3%         | 7,768         | 7,176        | 8.2%         |
| Other expenses                         | 1,934        | 1,838        | 5.2%         | 1,790        | 8.1%         | 3,724         | 3,558        | 4.7%         |
| <b>EBITDA</b>                          | <b>5,827</b> | <b>4,970</b> | <b>17.2%</b> | <b>4,832</b> | <b>20.6%</b> | <b>10,660</b> | <b>9,028</b> | <b>18.1%</b> |
| <b>EBITDA Margin*</b>                  | <b>21.2%</b> | <b>20.6%</b> |              | <b>19.0%</b> |              | <b>20.1%</b>  | <b>19.4%</b> |              |
| Depreciation and amortisation expenses | 1,171        | 1,117        | 4.8%         | 1,116        | 5.0%         | 2,287         | 2,197        | 4.1%         |
| EBIT                                   | 4,656        | 3,853        | 20.8%        | 3,717        | 25.3%        | 8,373         | 6,830        | 22.6%        |
| <b>EBIT Margin*</b>                    | <b>16.9%</b> | <b>16.0%</b> |              | <b>14.6%</b> |              | <b>15.8%</b>  | <b>14.7%</b> |              |
| Finance Cost                           | 719          | 798          | -9.9%        | 738          | -2.7%        | 1,457         | 1,611        | -9.6%        |
| PBT                                    | 3,938        | 3,055        | 28.9%        | 2,978        | 32.2%        | 6,916         | 5,219        | 32.5%        |
| Tax                                    | 937          | 842          | 11.3%        | 859          | 9.2%         | 1,796         | 1,354        | 32.7%        |
| <b>PAT</b>                             | <b>3,000</b> | <b>2,213</b> | <b>35.6%</b> | <b>2,120</b> | <b>41.5%</b> | <b>5,120</b>  | <b>3,865</b> | <b>32.5%</b> |
| <b>PAT Margin*</b>                     | <b>10.9%</b> | <b>9.2%</b>  |              | <b>8.3%</b>  |              | <b>9.7%</b>   | <b>8.3%</b>  |              |

\* Margins are calculated on Revenue from Operations.

# Q2 & H1 FY 26 Financial Performance (Standalone)

| Particulars (INR in Lacs)              | Q2 FY 26     | Q2 FY 25     | YoY%         | Q1 FY 26     | QoQ%         | H1 FY 26      | H1 FY 25     | YoY%         |
|--|--------------|--------------|--------------|--------------|--------------|---------------|--------------|--------------|
| Revenue from Operations                | 26,978       | 23,467       | 15.0%        | 24,980       | 8.0%         | 51,958        | 45,157       | 15.1%        |
| Other Income                           | 778          | 750          | 3.8%         | 696          | 11.9%        | 1,474         | 1,188        | 24.1%        |
| Total Income                           | 27,757       | 24,217       | 14.6%        | 25,676       | 8.1%         | 53,432        | 46,345       | 15.3%        |
| Operative Expenses                     | 16,286       | 14,100       | 15.5%        | 15,445       | 5.4%         | 31,730        | 27,132       | 17.0%        |
| Employee Benefit Expenses              | 3,825        | 3,471        | 10.2%        | 3,731        | 2.5%         | 7,556         | 6,936        | 8.9%         |
| Other expenses                         | 1,851        | 1,717        | 7.8%         | 1,717        | 7.8%         | 3,568         | 3,343        | 6.7%         |
| <b>EBITDA</b>                          | <b>5,794</b> | <b>4,928</b> | <b>17.6%</b> | <b>4,784</b> | <b>21.1%</b> | <b>10,578</b> | <b>8,934</b> | <b>18.4%</b> |
| <b>EBITDA Margin*</b>                  | <b>21.5%</b> | <b>21.0%</b> |              | <b>19.1%</b> |              | <b>20.4%</b>  | <b>19.8%</b> |              |
| Depreciation and amortisation expenses | 1,124        | 1,060        | 6.0%         | 1,066        | 5.4%         | 2,190         | 2,083        | 5.2%         |
| EBIT                                   | 4,670        | 3,868        | 20.7%        | 3,718        | 25.6%        | 8,388         | 6,852        | 22.4%        |
| <b>EBIT Margin*</b>                    | <b>17.3%</b> | <b>16.5%</b> |              | <b>14.9%</b> |              | <b>16.1%</b>  | <b>15.2%</b> |              |
| Finance Cost                           | 693          | 760          | -8.8%        | 711          | -2.5%        | 1,404         | 1,530        | -8.2%        |
| PBT                                    | 3,977        | 3,108        | 28.0%        | 3,007        | 32.3%        | 6,984         | 5,322        | 31.2%        |
| Tax                                    | 980          | 852          | 15.0%        | 865          | 13.3%        | 1,845         | 1,374        | 34.3%        |
| <b>PAT</b>                             | <b>2,996</b> | <b>2,256</b> | <b>32.8%</b> | <b>2,142</b> | <b>39.9%</b> | <b>5,138</b>  | <b>3,947</b> | <b>30.2%</b> |
| <b>PAT Margin*</b>                     | <b>11.1%</b> | <b>9.6%</b>  |              | <b>8.6%</b>  |              | <b>9.9%</b>   | <b>8.7%</b>  |              |

\* Margins are calculated on Revenue from Operations.

# Q2 FY 26

## Condensed Balance Sheet

| Standalone                               |                |                | Consolidated                             |                |                |
|--|----------------|----------------|--|----------------|----------------|
| Particulars (INR in Lacs)                | H1 FY26        | FY25           | Particulars (INR in Lacs)                | H1 FY26        | FY25           |
| <b>Total Shareholders Funds</b>          | <b>88,692</b>  | <b>84,180</b>  | <b>Total Shareholders Funds</b>          | <b>88,848</b>  | <b>84,355</b>  |
| Total Loans                              | 23,003         | 23,604         | Total Loans                              | 23,568         | 24,582         |
| Other Long Term Liabilities / Provisions | 9,162          | 8,970          | Other Long Term Liabilities / Provisions | 8,968          | 8,825          |
| <b>Total Sources of Funds</b>            | <b>120,856</b> | <b>116,754</b> | <b>Total Sources of Funds</b>            | <b>121,384</b> | <b>117,762</b> |
| Net Fixed Assets                         | 81,710         | 76,951         | Net Fixed Assets                         | 82,890         | 78,510         |
| Other Non Current Assets                 | 8,816          | 4,625          | Other Non Current Assets                 | 7,613          | 3,345          |
| <b>Total Non Current Assets</b>          | <b>90,526</b>  | <b>81,576</b>  | <b>Total Non Current Assets</b>          | <b>90,503</b>  | <b>81,854</b>  |
| Net Current Assets                       | (4,355)        | (4,148)        | Net Current Assets                       | (3,928)        | (3,646)        |
| Cash and Bank Balances                   | 34,685         | 39,326         | Cash and Bank Balances                   | 34,809         | 39,554         |
| <b>Total Application of Funds</b>        | <b>120,856</b> | <b>116,754</b> | <b>Total Application of Funds</b>        | <b>121,384</b> | <b>117,762</b> |

# Disclosure

This presentation contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Artemis Medicare Services future business developments and economic performance.

While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Artemis Medicare Services Limited undertakes no obligation to publicly revise any forward looking statements to reflect future /likely events or circumstances.

## For further information, please contact:

**Sanjiv K Kothari**  
Chief Financial Officer  
Artemis Medicare Services Ltd.

+91 124 4511 111  
[Sanjiv.kothari@artemishospitals.com](mailto:Sanjiv.kothari@artemishospitals.com)

**Mr. Rudra Narayan Acharjee**  
Head-Investor Relations, M&A, Org Growth  
Artemis Medicare Services Ltd.

+91 124 4511 111  
[rudra.acharjee@artemishospitals.com](mailto:rudra.acharjee@artemishospitals.com)

**Simran Malhotra / Anvita Raghuram**  
Churchgate Partners

+91 22 6169 5988  
[Artemisteam@churchgatepartners.com](mailto:Artemisteam@churchgatepartners.com)



# Thank You

---

ARTEMIS<sup>®</sup>  
H O S P I T A L S

OUR SPECIALITY IS YOU

**Artemis Medicare Services Ltd.**  
Sector 51, Gurugram - 122001, Haryana, India  
**Phone: +91-124-4511 111**

---

[www.artemishospitals.com](http://www.artemishospitals.com)